Effects of decoctions prepared from Aconitum carmichaeli, Aconitum kusnezoffii and Tripterygium wilfordii on serum lactate dehydrogenase activity and histology of liver, kidney, heart and gonad in mice

Comparison of Bioavailability of 1α-Hydroxycholecalciferol and Cholecalciferol in Broiler Chicken Diets

The present study aims to compare the relative bioavailability (RBV) of 1α-hydroxycholecalciferol (1α-OH-D₃) to cholecalciferol (D₃) in 1- to 21-d-old broiler chicks fed with calcium (Ca)- and phosphorus (P)-deficient diets. A total of 400 male of 1-d-old Ross 308 broilers were randomly assigned to 8 treatments with 5 replicates each. Five levels of D₃ (0, 2.5, 5, 10, and 20 µg/kg) and three levels of 1α-OH-D₃ (1.25, 2.5, and 5 µg/kg) were added to a basal diet. The basal diet contained 0.50% Ca and 0.25% non-phytate phosphorus (NPP), without D₃. The RBV of 1α-OHD₃ to D₃ was determined by the slope ratio method. Using bodyweight gain, feed intake, feed efficiency, and plasma Ca as criteria, the RBV of 1α-OH-D₃ to D₃ were 4.78, 4.75, 4.50, and 4.21, respectively. Using tibia breaking-strength, weight, length, width, ash weight and content, and Ca and P content as criteria, the RBV of 1α-OH-D₃ to D₃ were 5.58, 5.16, 4.42, 4.70, 5.03, 4.46, 4.70, and 4.79. Using femur weight, length, width, ash weight and content, and Ca and P content as criteria, the RBV of 1α-OH-D₃ to D₃ were 5.09, 4.43, 3.19, 5.83, 5.21, 5.27, and 5.31. Using metatarsus weight, length, width, ash weight and content, and Ca and P content as criteria, the RBV of 1α-OHD₃ to D₃ were 5.00, 4.05, 5.94, 4.73, 5.33, 5.64, and 4.28. These data indicate that the RBV of 1α-OH-D₃ to D₃ is 4.84 in promoting growth performance and bone mineralization in broilers from 1 to 21 d of age.

Pregnancy outcomes, embryonic and fetal development in maternal exposure to Chinese medicines

Chinese medicine is a common name for a collection of Chinese Materia Medica with therapeutic properties for medical treatment and healing. Similar to Western pharmaceuticals, Chinese medicines are not free of risk, and have the potential to cause adverse pregnancy outcomes and affect embryonic and fetal development. However, most clinical data concerning safety of maternal exposure to Chinese medicines during pregnancy are not available and the conclusion remains elusive. Some individual clinical trials of Chinese medicines reported some minor adverse effects during pregnancy, whereas few animal studies identified some adverse maternal and perinatal effects, as well as embryotoxic potentials. Basic research and mechanistic studies of the teratogenicity of Chinese medicines are still lacking. There is an urgent need for testing the safety of Chinese medicines before recommendation and commercialization. Until more reliable and scientific research data become available, clinicians should consider both the risks and benefits before recommending Chinese medicines to pregnant women. More systematic investigations of the safety implications of the use of Chinese medicines are highly recommended, in addition to more clinical trials with a larger sample size to confirm its safety during pregnancy. This review includes a critical overview of available clinical and experimental data and provides directions to study the safety issue of Chinese medicines for pregnancy.

Evidence-based toxicity evaluation and scheduling of Chinese herbal medicines

ETHNOPHARMACOLOGICAL RELEVANCE

While there is an increasing number of toxicity report cases and toxicological studies on Chinese herbal medicines, the guidelines for toxicity evaluation and scheduling of Chinese herbal medicines are lacking.

AIM

The aim of this study was to review the current literature on potentially toxic Chinese herbal medicines, and to develop a scheduling platform which will inform an evidence-based regulatory framework for these medicines in the community.

MATERIALS AND METHODS

The Australian and Chinese regulations were used as a starting point to compile a list of potentially toxic herbs. Systematic literature searches of botanical and pharmaceutical Latin name, English and Chinese names and suspected toxic chemicals were conducted on Medline, PubMed and Chinese CNKI databases.

RESULTS

Seventy-four Chinese herbal medicines were identified and five of them were selected for detailed study. Preclinical and clinical data were summarised at six levels. Based on the evaluation criteria, which included risk-benefit analysis, severity of toxic effects and clinical and preclinical data, four regulatory classes were proposed: Prohibited for medicinal usage, which are those with high toxicity and can lead to injury or death, e.g., aristolochia; Restricted for medicinal usage, e.g., aconite, asarum, and ephedra; Required warning label, e.g., coltsfoot; and Over-the-counter herbs for those herbs with a safe toxicity profile.

CONCLUSION

Chinese herbal medicines should be scheduled based on a set of evaluation criteria, to ensure their safe use and to satisfy the need for access to the herbs. The current Chinese and Australian regulation of Chinese herbal medicines should be updated to restrict the access of some potentially toxic herbs to Chinese medicine practitioners who are qualified through registration.

Study on pretreatment of FPS-1 in rats with hepatic ischemia-reperfusion injury

This study was designed to determine whether FPS-1, the water-soluble polysaccharide isolated from fuzi, protected against hepatic damage in hepatic ischemia-reperfusion injury in rats, and its mechanism. SD rats were subjected to 60 min of hepatic ischemia, followed by 120 min reperfusion. FPS-1 (160 mg/kg/day) was administered orally for 5 days before ischemia-reperfusion injury in treatment group. Serum aspartate aminotransferase (AST), alanine aminotransferase (ALT) and albumin (ALB) were assayed to evaluate liver functions. Liver samples were taken for histological examination and determination of malondialdehyde (MDA), superoxide dismutase (SOD), that catalase (CAT) in liver. Na(+)-K(+)-ATPase and Ca(2+)-ATPase in mitochondria were measured with colorimetry method. Morphological changes were also investigated by using both light microscopy and electron microscopy (EM). In addition, apoptosis and oncosis were detected by Annexin V-FITC/PI immunofluorescent flow cytometry analysis. Serum AST and ALT levels were elevated in groups exposed to ischemia-reperfusion (p < 0.05). Ischemia-reperfusion caused a marked increase in MDA level, and significant decreases in hepatic SOD and CAT (p < 0.05). Na(+)-K(+)-ATPase and Ca(2+)-ATPase were reduced in ischemia-reperfusion groups compared to the sham group (p < 0.05). Oncosis and apoptosis were also observed in ischemia-reperfusion groups. Pretreatment with FPS-1 reversed all these biochemical parameters as well as histological alterations, evidently by increased SOD, CAT, reduced MDA and histological scores compared to the model group (p < 0.05). FPS-1 could attenuate the necrotic states by the detection of immunofluorescent flow cytometry analysis. Pretreatment with FPS-1 reduced hepatic ischemia-reperfusion injury through its potent antioxidative effects and attenuation of necrotic states.